{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T10:05:56Z","timestamp":1789725956748,"version":"4.0.1"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"AiCuris AG"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immunocompromised patients are at risk for severe, prolonged herpes simplex virus (HSV) recurrences. Refractory disease and intolerance to standard therapy drive an unmet medical need. Pritelivir, a novel HSV helicase-primase inhibitor, has shown favorable tolerability and efficacy in immunocompetent adults.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>PRIOH-1, a multicenter, randomized, open-label Phase 2 trial, compared oral pritelivir (400-mg loading dose followed by 100\u2005mg daily) with intravenous foscarnet (40\u2005mg\/kg q8h or 60\u2005mg\/kg q12h) for up to 28 days in immunocompromised adults with acyclovir-refractory HSV (Part A). Participants with refractoriness\/intolerance to foscarnet received pritelivir (Part B). The primary end point was time to lesion healing; secondary end points included healing rate, HSV DNA detection, and resistance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twenty-two participants enrolled in Part A, 8 in Part B. In Part A, median time to healing was 26.0 days (95% CI, 13.0\u201331.0) with pritelivir, vs not estimable (95% CI, 20.0\u2013NE) with foscarnet (HR, 2.7; 95% CI, 0.33\u201321.8; P = .34). Investigator-assessed healing rates were 93% with pritelivir and 57% with foscarnet, a 36.2% difference (95% CI, \u221210.1 to 74.1; P = .077). Postbaseline HSV DNA detection rates were 34.8% and 50.0%, respectively (P = .42). Treatment-emergent adverse events occurred in 60% of pritelivir- and 100% of foscarnet-treated participants; serious treatment-emergent adverse events were less frequent with pritelivir. In Part B, the median time to healing was 19.0 days, with a 63% healing rate.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Pritelivir demonstrated encouraging efficacy and favorable safety in immunocompromised adults with limited treatment options, supporting Phase 3 evaluation for the treatment of refractory HSV infection in this population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ofid\/ofag539","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T11:49:43Z","timestamp":1787226583000},"source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and Safety of Pritelivir vs Foscarnet for the Treatment of Acyclovir-Refractory Herpes Simplex Virus Infection in Immunocompromised Adults: A Randomized, Open-Label Phase 2 Trial"],"prefix":"10.1093","volume":"13","author":[{"given":"Camille N","family":"Kotton","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Massachusetts General Hospital , Boston, Massachusetts ,","place":["USA"]},{"name":"Harvard Medical School , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9918-9493","authenticated-orcid":false,"given":"Kimberly A","family":"Workowski","sequence":"additional","affiliation":[{"name":"Department of Medicine, Emory University School of Medicine , Atlanta, Georgia ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5994-2727","authenticated-orcid":false,"given":"Princy N","family":"Kumar","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases and Tropical Medicine, Georgetown University Medical Center , Washington, District of Columbia ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin K","family":"Avery","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Johns Hopkins University School of Medicine , Baltimore, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0277-3088","authenticated-orcid":false,"given":"Roy F","family":"Chemaly","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center , Houston, Texas ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas C","family":"Issa","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases Brigham and Women's Hospital and Dana-Farber Cancer Institute , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moti","family":"Ramgopal","sequence":"additional","affiliation":[{"name":"Midway Immunology and Research Center , Fort Pierce, Florida ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua T","family":"Schiffer","sequence":"additional","affiliation":[{"name":"Vaccine and Infectious Disease Division, Fred Hutchison Cancer Center , Seattle, Washington ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joerg","family":"Albrecht","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Cook County Health , Chicago, Illinois ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Hollis R","family":"O\u2019Neal","sequence":"additional","affiliation":[{"name":"Department of Medicine, Louisiana State University Health Sciences Center , Baton Rouge, Louisiana ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0774-1058","authenticated-orcid":false,"given":"Pranatharthi","family":"Chandrasekar","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Karmanos Cancer Center, Wayne State University School of Medicine , Detroit, Michigan ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya S","family":"Schreibman","sequence":"additional","affiliation":[{"name":"CAN Community Health , Sarasota, Florida ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1677-3994","authenticated-orcid":false,"given":"Mayur","family":"Ramesh","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Henry Ford Health System , Detroit, Michigan ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3347-9671","authenticated-orcid":false,"given":"Michael G","family":"Ison","sequence":"additional","affiliation":[{"name":"National Institutes of Health , Bethesda, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0205-4970","authenticated-orcid":false,"given":"Melanie E","family":"Sumner","sequence":"additional","affiliation":[{"name":"AiCuris Anti-Infective Cures AG , Wuppertal ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Dane","sequence":"additional","affiliation":[{"name":"Danestat Consulting Limited , Macclesfield, Cheshire ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernadette","family":"Surujbally","sequence":"additional","affiliation":[{"name":"AiCuris Anti-Infective Cures AG , Wuppertal ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burkhard","family":"Timmler","sequence":"additional","affiliation":[{"name":"AiCuris Anti-Infective Cures AG , Wuppertal ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manickam","family":"Rangaraju","sequence":"additional","affiliation":[{"name":"AiCuris Anti-Infective Cures AG , Wuppertal ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2891-079X","authenticated-orcid":false,"given":"Genofeva A","family":"Papanicolaou","sequence":"additional","affiliation":[{"name":"Department of Subspecialty Medicine, Infectious Disease Service, Memorial Sloan Kettering Cancer Center , New York, New York ,","place":["USA"]},{"name":"Department of Medicine, Weill Cornell Medicine, Cornell University , New York, New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5670-4814","authenticated-orcid":false,"given":"Alexander","family":"Birkmann","sequence":"additional","affiliation":[{"name":"AiCuris Anti-Infective Cures AG , Wuppertal ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3486-6438","authenticated-orcid":false,"given":"Anna","family":"Wald","sequence":"additional","affiliation":[{"name":"Division of Allergy and Infectious Diseases, Department of Medicine, Department of Epidemiology, Department of Laboratory Medicine and Pathology, University of Washington , Seattle, Washington ,","place":["USA"]},{"name":"Fred Hutchinson Cancer Center , Seattle, Washington ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,31]]},"reference":[{"key":"2026091805323872000_ofag539-B1","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1136\/sextrans-2024-056307","article-title":"Estimated global and regional incidence and prevalence of herpes simplex virus infections and genital ulcer disease in 2020: mathematical modelling analyses","volume":"101","author":"Harfouche","year":"2025","journal-title":"Sex Transm Infect"},{"key":"2026091805323872000_ofag539-B2","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1586\/14787210.5.2.231","article-title":"Interactions and management issues in HSV and HIV coinfection","volume":"5","author":"Ramaswamy","year":"2007","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2026091805323872000_ofag539-B3","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/bmt.2008.386","article-title":"Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the second European Conference on Infections in Leukemia","volume":"43","author":"Styczynski","year":"2009","journal-title":"Bone Marrow Transplant"},{"key":"2026091805323872000_ofag539-B4","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3390\/v14020205","article-title":"Outcomes of herpes simplex virus pneumonitis in critically ill patients","volume":"14","author":"Chang","year":"2022","journal-title":"Viruses"},{"key":"2026091805323872000_ofag539-B5","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1399-0012.2009.01108.x","article-title":"Herpes simplex virus sepsis and acute liver failure","volume":"23(Suppl 21)","author":"Riediger","year":"2009","journal-title":"Clin Transplant"},{"key":"2026091805323872000_ofag539-B6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr7004a1","article-title":"Sexually transmitted infections treatment guidelines, 2021","volume":"70","author":"Workowski","year":"2021","journal-title":"MMWR Recomm Rep"},{"key":"2026091805323872000_ofag539-B7","doi-asserted-by":"crossref","first-page":"e13526","DOI":"10.1111\/ctr.13526","article-title":"Herpes simplex virus infections in solid organ transplantation: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice","volume":"33","author":"Lee","year":"2019","journal-title":"Clin Transplant"},{"key":"2026091805323872000_ofag539-B8","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1016\/j.cmi.2025.04.046","article-title":"Herpes simplex virus and drug resistance-comprehensive update on resistance mutations and implications for clinical management: a narrative review","volume":"31","author":"D\u00e4hne","year":"2025","journal-title":"Clin Microbiol Infect"},{"key":"2026091805323872000_ofag539-B9","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1093\/cid\/ciae638","article-title":"Refractory and resistant herpes simplex virus mucocutaneous infections in immunocompromised patients: literature review and proposed definitions for use in clinical trials","volume":"81","author":"Chemaly","year":"2025","journal-title":"Clin Infect Dis"},{"key":"2026091805323872000_ofag539-B10","doi-asserted-by":"crossref","first-page":"5716","DOI":"10.1073\/pnas.74.12.5716","article-title":"Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine","volume":"74","author":"Elion","year":"1977","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026091805323872000_ofag539-B11","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1128\/AAC.00615-10","article-title":"Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management","volume":"55","author":"Piret","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2026091805323872000_ofag539-B12","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1056\/NEJM198202113060606","article-title":"Resistance to antiviral drugs of herpes simplex virus isolated from a patient treated with Acyclovir","volume":"306","author":"Crumpacker","year":"1982","journal-title":"N Engl J Med"},{"key":"2026091805323872000_ofag539-B13","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1001\/archinte.163.1.76","article-title":"Acyclovir-resistant genital herpes among persons attending sexually transmitted disease and human immunodeficiency virus clinics","volume":"163","author":"Reyes","year":"2003","journal-title":"Arch Intern Med"},{"key":"2026091805323872000_ofag539-B14","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1097\/QCO.0000000000000288","article-title":"Antiviral resistance in herpes simplex virus and varicella-zoster virus infections: diagnosis and management","volume":"29","author":"Piret","year":"2016","journal-title":"Curr Opin Infect Dis"},{"key":"2026091805323872000_ofag539-B15","doi-asserted-by":"crossref","first-page":"115322","DOI":"10.1016\/j.bcp.2022.115322","article-title":"Acyclovir resistance in herpes simplex viruses: prevalence and therapeutic alternatives","volume":"206","author":"Schalkwijk","year":"2022","journal-title":"Biochem Pharmacol"},{"key":"2026091805323872000_ofag539-B16","author":"Centers for Disease Control and Prevention"},{"key":"2026091805323872000_ofag539-B17","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1056\/NEJM199108223250805","article-title":"A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group","volume":"325","author":"Safrin","year":"1991","journal-title":"N Engl J Med"},{"key":"2026091805323872000_ofag539-B18","volume-title":"Foscavir (Foscarnet Sodium) Injection, Solution [Prescribing Information]","author":"US Food and Drug Administration","year":"2017"},{"key":"2026091805323872000_ofag539-B19","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1128\/JCM.42.1.242-249.2004","article-title":"Surveillance network for herpes simplex virus resistance to antiviral drugs: 3-year follow-up","volume":"42","author":"Danve-Szatanek","year":"2004","journal-title":"J Clin Microbiol"},{"key":"2026091805323872000_ofag539-B20","doi-asserted-by":"crossref","first-page":"13614","DOI":"10.1021\/acs.jmedchem.2c00668","article-title":"Discovery, chemistry, and preclinical development of pritelivir, a novel treatment option for acyclovir-resistant herpes simplex virus infections","volume":"65","author":"Birkmann","year":"2022","journal-title":"J Med Chem"},{"key":"2026091805323872000_ofag539-B21","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1056\/NEJMoa1301150","article-title":"Helicase-primase inhibitor pritelivir for HSV-2 infection","volume":"370","author":"Wald","year":"2014","journal-title":"N Engl J Med"},{"key":"2026091805323872000_ofag539-B22","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1001\/jama.2016.18189","article-title":"Effect of pritelivir compared with valacyclovir on genital HSV-2 shedding in patients with frequent recurrences: a randomized clinical trial","volume":"316","author":"Wald","year":"2016","journal-title":"JAMA"},{"key":"2026091805323872000_ofag539-B23","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1002\/cpdd.1241","article-title":"First-in-human, single- and multiple-ascending-dose, food-effect, and absolute bioavailability trials to assess the pharmacokinetics, safety, and tolerability of pritelivir, a nonnucleoside helicase-primase inhibitor against herpes simplex virus in healthy subjects","volume":"12","author":"Kropeit","year":"2023","journal-title":"Clin Pharmacol Drug Dev"},{"key":"2026091805323872000_ofag539-B24","doi-asserted-by":"crossref","first-page":"e0173222","DOI":"10.1128\/aac.01732-22","article-title":"Salvage treatment of refractory HSV oral lesions with pritelivir in allogeneic hematopoietic cell transplant recipients","volume":"67","author":"Bosetti","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"2026091805323872000_ofag539-B25","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1177\/09564624211006568","article-title":"Use of pritelivir in refractory aciclovir-resistant herpes simplex virus type 2","volume":"32","author":"Cannon","year":"2021","journal-title":"Int J STD AIDS"},{"key":"2026091805323872000_ofag539-B26","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1093\/jac\/dkac165","article-title":"Pritelivir for recurrent aciclovir-resistant herpes simplex virus 2 infections in immunocompromised patients","volume":"77","author":"Serris","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"2026091805323872000_ofag539-B27","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3390\/pharmaceutics15010163","article-title":"Optimizing antiviral dosing for HSV and CMV treatment in immunocompromised patients","volume":"15","author":"Huntjens","year":"2023","journal-title":"Pharmaceutics"},{"key":"2026091805323872000_ofag539-B28","first-page":"108","article-title":"Pritelivir for the treatment of nucleoside analogue-resistant orolabial herpes simplex virus 2 in a person living with HIV","volume":"9","author":"Purssell","year":"2024","journal-title":"J Assoc Med Microbiol Infect Dis Can"},{"key":"2026091805323872000_ofag539-B29","author":"AiCuris"},{"key":"2026091805323872000_ofag539-B30","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1128\/JCM.40.7.2609-2611.2002","article-title":"Quantitative stability of DNA after extended storage of clinical specimens as determined by real-time PCR","volume":"40","author":"Jerome","year":"2002","journal-title":"J Clin Microbiol"},{"key":"2026091805323872000_ofag539-B31","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1001\/jama.2023.28019","article-title":"Prevalence of immunosuppression among US adults","volume":"331","author":"Martinson","year":"2024","journal-title":"JAMA"},{"key":"2026091805323872000_ofag539-B32","doi-asserted-by":"crossref","first-page":"ofae046","DOI":"10.1093\/ofid\/ofae046","article-title":"A multicenter assessment of the outcomes and toxicities of foscarnet for treatment of acyclovir-resistant mucocutaneous herpes simplex in immunocompromised patients","volume":"11","author":"Hammond","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"2026091805323872000_ofag539-B33","doi-asserted-by":"crossref","first-page":"105521","DOI":"10.1016\/j.antiviral.2022.105521","article-title":"Meeting report: 35th International Conference on Antiviral Research in Seattle, Washington, USA\u2014March 21\u201325, 2022","volume":"211","author":"Spengler","year":"2023","journal-title":"Antiviral Res"},{"key":"2026091805323872000_ofag539-B34","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1177\/095632020701800102","article-title":"High frequency of spontaneous helicase-primase inhibitor (BAY 57-1293) drug-resistant variants in certain laboratory isolates of HSV-1","volume":"18","author":"Biswas","year":"2007","journal-title":"Antivir Chem Chemother"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofag539\/70767213\/ofag539.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/9\/ofag539\/70767213\/ofag539.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/9\/ofag539\/70767213\/ofag539.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T09:33:32Z","timestamp":1789724012000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofag539\/8769029"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,31]]},"references-count":34,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofag539","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,8,31]]},"article-number":"ofag539"}}